Tuberculosis is a disease of poverty, and economic distress with 1.4 million deaths annually 1 and the growing challenge of drug resistance is adding to the global health crisis WHO guidelines support the expansion of tuberculosis diagnostics in resource-limited countries, enabling patients to receive timely diagnosis leading to proper tr

New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA).

Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June 2021 - Roche today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and

Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive care First and only cancer immunotherapy to show positive Phase III results in the adjuvant lung cancer setting New adjuvant treatment options are urgently needed in early lung cancer to

Basel, 28 April 2021 - Roche today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible fo

The authorisation enables emergency use of Actemra /RoActemra for the treatment of COVID-19 in hospitalised adult and paediatric patients - Basel, 25 June 2021 - Roche announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra (tocilizumab) for

Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years after completion of a one-year fixed-duration treatment with Venclexta /Venclyxto plus Gazyva /Gazyvaro 1 New phase III MURANO study data suggested

With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemia In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq's fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer o

About 90,000 women globally die from endometrial cancer each year 1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly ) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help